212 related articles for article (PubMed ID: 37919061)
1. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features.
Maimaiti A; Liu Y; Abulaiti A; Wang X; Feng Z; Wang J; Mijiti M; Turhon M; Alimu N; Wang Y; Liang W; Jiang L; Pei Y
J Mol Neurosci; 2023 May; 73(4-5):269-286. PubMed ID: 37067735
[TBL] [Abstract][Full Text] [Related]
3. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
Xu S; Wang Z; Ye J; Mei S; Zhang J
Front Oncol; 2021; 11():729103. PubMed ID: 34568059
[TBL] [Abstract][Full Text] [Related]
4. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
Chen J; Li Y; Han X; Pan Y; Qian X
Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
[TBL] [Abstract][Full Text] [Related]
5. A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing.
Xiang X; Kang J; Jiang J; Zhang Y; Zhang Y; Li L; Peng X
Front Immunol; 2023; 14():1198391. PubMed ID: 37449209
[TBL] [Abstract][Full Text] [Related]
6. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
7. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
8. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
9. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
PeerJ; 2024; 12():e16874. PubMed ID: 38406287
[TBL] [Abstract][Full Text] [Related]
10. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
11. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma.
Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B
Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059
[TBL] [Abstract][Full Text] [Related]
12. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
13. Identification of heterogeneous subtypes and a prognostic model for gliomas based on mitochondrial dysfunction and oxidative stress-related genes.
Li J; Wang S; Chi X; He Q; Tao C; Ding Y; Wang J; Zhao J; Wang W
Front Immunol; 2023; 14():1183475. PubMed ID: 37334354
[TBL] [Abstract][Full Text] [Related]
14. Integrating bulk and single-cell RNA sequencing data reveals epithelial-mesenchymal transition molecular subtype and signature to predict prognosis, immunotherapy efficacy, and drug candidates in low-grade gliomas.
Wang C; He Z
Front Pharmacol; 2023; 14():1276466. PubMed ID: 38053842
[No Abstract] [Full Text] [Related]
15. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes based on centrosome-related genes can predict prognosis and therapeutic responsiveness in patients with low-grade gliomas.
Zhang G; Tai P; Fang J; Chen A; Chen X; Cao K
Front Oncol; 2023; 13():1157115. PubMed ID: 37051542
[TBL] [Abstract][Full Text] [Related]
17. A Prognostic Microenvironment-Related Immune Signature
Qiu H; Li Y; Cheng S; Li J; He C; Li J
Front Oncol; 2020; 10():580263. PubMed ID: 33425732
[TBL] [Abstract][Full Text] [Related]
18. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
Front Immunol; 2022; 13():982033. PubMed ID: 36052073
[TBL] [Abstract][Full Text] [Related]
19. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
20. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
